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ABSTRACT 
Hypothesis: TBC1D1 is a Rab GTPase activating protein (RabGAP) that has been implicated in 
regulating GLUT4 trafficking. TBC1D1 can be phosphorylated by the AMP-activated protein 
kinase (AMPK) on Ser231, which consequently interacts with 14-3-3 proteins. Given the key role 
for AMPK in regulating insulin-independent muscle glucose uptake, we hypothesized that 
TBC1D1 Ser231 phosphorylation and/or 14-3-3 binding may mediate AMPK-governed glucose 
homeostasis.  
Methods: Whole-body glucose homeostasis and muscle glucose uptake were assayed in mice 
bearing a TBC1D1Ser231Ala knockin mutation or harboring skeletal muscle specific AMPKα1/α2 
double knockout mutations in response to an AMPK-activating agent, 5-aminoimidazole-4-
carboxamide-1-ß-D-ribofuranoside (AICAR). Exercise-induced muscle glucose uptake and 
exercise capacity were also determined in the TBC1D1Ser231Ala knockin mice. 
Results: Skeletal muscle specific deletion of AMPKα1/α2 in mice prevented AICAR-induced 
hypoglycemia and muscle glucose uptake. The TBC1D1Ser231Ala knockin mutation also 
attenuated the glucose-lowering effect of AICAR in mice. Glucose uptake and cell surface 
GLUT4 content were significantly lower in muscle isolated from the TBC1D1Ser231Ala knockin 
mice upon stimulation with a submaximal dose of AICAR. However, this TBC1D1Ser231Ala 
knockin mutation neither impaired exercise-induced muscle glucose uptake nor affected exercise 
capacity in mice.  
Conclusions: TBC1D1 Ser231 phosphorylation and/or 14-3-3 binding partially mediates AMPK-
governed glucose homeostasis and muscle glucose uptake in a context-dependent manner. 
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INTRODUCTION 
 Type 2 diabetes has become pandemic in the last few decades, which urges novel 
therapeutics to prevent, treat or cure the disease. Since insulin sensitivity is generally decreased 
in type 2 diabetic patients, insulin-independent treatment is commonly considered to combat type 
2 diabetes. The energy sensor AMP-activated protein kinase (AMPK) has been proposed as an 
attractive drug target for treatment of type 2 diabetes as its activation brings about many of the 
acute and chronic beneficial effects of exercise and promotes muscle glucose uptake in an 
insulin-independent mechanism [1, 2]. 
The heterotrimeric AMPK holoenzyme consists of a catalytic subunit α (α1 and α2), a 
regulatory subunit γ (γ1, γ2 and γ3), and a third subunit β (β1 and β2) that bridges α and γ 
subunits [1]. AMPK regulates whole-body glucose homeostasis by various mechanisms [1, 3, 4], 
one of which is via control of muscle glucose uptake by promoting translocation of the glucose 
transporter 4 (GLUT4) from its intracellular storage sites onto plasma membrane [5]. Whole-
body deletion of AMPK α2 or β2 subunit, or overexpression of a dominant inhibitory mutant of 
AMPK in muscle, attenuated the hypoglycemic effect of AICAR in mice. Furthermore, genetic 
inactivation of AMPK α2, β2 or γ3 subunit, or overexpression of the dominant inhibitory mutant 
of AMPK, all inhibit AICAR-stimulated muscle glucose uptake [6-10]. However, the regulatory 
mechanism of AMPK-dependent GLUT4 translocation remains to be elucidated. GLUT4 also 
mediates insulin-stimulated glucose uptake into skeletal muscle and adipose, whose translocation 
in response to insulin is regulated by the protein kinase B (PKB) pathway [11]. 
Two related RabGAPs, AS160 (Akt substrate of 160 kDa) and TBC1D1, have been 
linked with type 2 diabetes and obesity, respectively [12-15]. These enzymes have also been 
implicated in regulating GLUT4 trafficking (reviewed by [16]). Both AS160 and TBC1D1 can 
be phosphorylated on multiple sites by protein kinases including PKB and AMPK (reviewed by 
[17]). Overexpression of an AS160-4P mutant (in which Ser325, Ser595, Thr649 and Ser758 were 
replaced by alanine) or a TBC1D1-3P mutant (in which alanine replaced Ser489, Thr499/Ser501, 
and Thr590) exerts a robust inhibition on insulin-stimulated GLUT4 translocation in 3T3-L1 
adipocytes [18, 19]. In contrast, overexpression of a TBC1D1-4P mutant (in which alanine 
replaced Ser231, Thr499, Thr590, and Ser621) decreased contraction-induced glucose uptake in 
mouse skeletal muscle [20]. Upon phosphorylation, both AS160 and TBC1D1 bind to regulatory 
14-3-3 proteins (reviewed by [17]). The AS160−14-3-3 interaction is regulated by insulin and 
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mainly mediated by phosphorylated Thr649 on AS160 [21, 22], whereas 14-3-3 binding to 
TBC1D1 is dependent on AMPK and mainly requires phosphorylated Ser231 on TBC1D1 [23, 
24]. Moreover, 14-3-3 binding to AS160 has been implicated in participating insulin-stimulated 
GLUT4 translocation in 3T3-L1 adipocytes [21]. On the basis of these findings, we put forward 
a hypothesis that AS160−14-3-3 interaction is required for insulin-stimulated GLUT4 trafficking 
and glucose homeostasis while 14-3-3 binding to TBC1D1 mediates AMPK-dependent GLUT4 
translocation and glucose homeostasis [17]. Towards addressing this hypothesis, we previously 
generated an AS160Thr649Ala knockin mouse model in which insulin-induced AS160-Thr649 
phosphorylation and its binding to 14-3-3s was prevented, and showed that the AS160Thr649Ala 
knockin mice exhibited insulin resistance mainly due to impaired GLUT4 translocation and 
glucose uptake into skeletal muscle in response to insulin [25]. In contrast, the AICAR-
stimulated muscle glucose uptake and hypoglycaemia, which are independent of insulin, were 
normal in these mice [26]. 
In this study we utilized a recently-reported TBC1D1Ser231Ala knockin mouse model in 
which the knockin mutation prevents AMPK-dependent phosphorylation of TBC1D1-Ser231 [27] 
to further test the above hypothesis. 
Materials and Methods 
Materials 
Recombinant human insulin was bought from Novo Nordisk (Denmark) and AICAR 
from Toronto Research Chemicals (Canada). Protein G-Sepharose was from GE-Healthcare 
(UK). 2-deoxy-D-[1,2-3H(N)]glucose and D-[1-14C]-mannitol were from PerkinElmer (USA). 
All other chemicals were from Sigma-Aldrich or Sangon Biotech (China). Total TBC1D1 
antibody is as previously described [23]. The commercial antibodies are listed in Supplementary 
Table 1. 
Mouse breeding and genotyping 
The Ethics Committees, initially at University of Dundee and latterly at Nanjing 
University, approved all animal protocols. Mice were kept under a light/dark cycle of 12 h. The 
TBC1D1Ser231Ala knockin mice were as previously described [27]. The AMPKα1f/f and 
AMPKα2f/f mice were as previously described [28], and they were mated with each other to 
obtain AMPKα1/α2f/f mice. The AMPKα1/α2f/f mice were then mated with the Myf5-Cre mice 
[29] to obtain the AMPKα1/α2f/f–Myf5-Cre mice that are the skeletal muscle-specific 
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AMPKα1/α2 knockout (AMPKα1/α2-mKO) mice. Genotyping was carried out using primers 
listed in Supplementary Table 2. 
Tissue lysis, immunoprecipitation, immunoblotting and 14-3-3 overlay 
Homoginization of mouse tissues and protein concentration measurement were carried 
out as previously described [26]. 
Immunoprecipitation of TBC1D1 proteins, immunoblotting and 14-3-3 overlay were 
carried out as previously described [23]. 
AICAR tolerance test and insulin tolerance test 
Mice were partially fasted for 4 h prior to AICAR or insulin tolerance test. Afterwards, 
basal blood glucose was measured using a Breeze 2 glucometer (Bayer) via tail bleeding. Mice 
were intraperitoneally injected either with AICAR (0.25 mg/g) for AICAR tolerance tests, or 
with insulin (0.75 mU/g) for insulin tolerance tests. After injection of AICAR or insulin, blood 
glucose levels were measured at the indicated time intervals. 
Muscle incubation, glucose uptake and photolabelling of cell surface GLUT4 in isolated 
muscle 
 Muscle isolation and glucose uptake were carried out as previously described [25]. 
Briefly, isolated muscles were incubated in KRB buffer (+/− AICAR) for 50 min. For 
biochemistry studies, muscles were then blotted dry and snap-frozen in liquid nitrogen for 
subsequent analysis. For glucose uptake, muscles were further incubated in KRB buffer (+/− 
AICAR) containing 2-deoxy-D-[1,2-3H(N)]glucose and D-[1-14C]-mannitol for 10 min. 
Radioisotopes in muscle lysates were determined using a Tri-Carb 2800TR scintillation counter 
(PerkinElmer). For the photolabelling experiment, cell surface GLUT4 in isolated EDL muscle 
was chemically tagged with the photolabel Bio-LC-ATB-BGPA and quantified as previously 
described [25]. 
Treadmill exercise 
 Two types of treadmill running tests, namely power test (short high-intensity run) and 
endurance test (long low-intensity run), were performed to assess maximal exercise performance 
in mice using a treadmill (Techman Soft, China) as previously described [30]. Briefly, mice were 
acclimated to treadmill running (5 min per day at 15 cm/sec, +5° slope and 0.3 mA electrical 
stimulation) for 5 days before the tests. For power tests, the treadmill was set with a +5° slope 
and 0.3 mA aversive electrical stimulation. Belt speed was set at 15 cm/sec initially and 
 6 
increased by 2 cm/sec every minute. As for endurance tests, the treadmill was set with a +5° 
slope and 0.3 mA aversive electrical stimulation. Belt speed was set at 15 cm/sec initially and 
increased by 3 cm/sec every 12-minutes. Running tests were terminated when mice failed to re-
engage on the treadmill despite aversive stimulation for more than 15 sec. 
Exercise-stimulated muscle glucose uptake in vivo 
 Exercise-stimulated muscle glucose uptake was carried out as previously described [31]. 
Briefly, mice were intraperitoneally injected with 10 μCi of 2-deoxy-D-[1,2-3H(N)]glucose 
immediately prior to rest or exercise. For the exercise group, mice were subjected to 35 min of 
treadmill running (30 cm/sec belt speed, +10° slope). For the resting group, mice were kept in 
home cages for 35 min. After exercise or rest, mice were terminated and gastrocnemius and 
quadriceps muscles were harvested for further analysis. An assumption was made that systemic 
delivery of the tracer was similar in all animals within each experimental group since the 
appearance of 2-deoxy-D-[1,2-3H(N)]glucose in the blood was not determined due to technical 
reasons. Muscle accumulation of phosphorylated 2-deoxy-D-[1,2-3H(N)]glucose was determined 
and used for calculation of in vivo muscle glucose uptake rates as previously described [25].    
Histology and imaging 
 Isolated soleus and EDL muscles were embedded in Tissue Freezing Medium 
(#14020108926, Leica), frozen in liquid nitrogen, and sectioned using a Leica RM2016 
microtome. Muscle fiber type (I, IIa, and IIb/IIx) in soelus and EDL muscle was determined 
using myosin ATPase staining as previously described [32]. After staining, pictures were taken 
on sections using an Olympus BX53F microscope. 
Immunofluorescence staining and imaging 
 Immunofluorescence staining of GLUT4 were performed in single muscle fibers as 
previously described [27]. Images were photographed using a Leica confocal microscope.  
Statistical analysis 
Data are given as mean ± SEM. Two-group comparisons were carried out via t-test, and 
multiple-group comparisons were performed with 2-way ANOVA using Prism software 
(GraphPad, San Diego, CA, USA). Differences were considered statistically significant at p  
0.05 that was indicated with an asterisk. NS indicates not significant. 
Results 
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Deletion of AMPKα1/α2 in skeletal muscle blunted the hypoglycemic effect of AICAR and 
AICAR-stimulated muscle glucose uptake 
 It has been shown that overexpression of the dominant inhibitory mutant of AMPK in 
skeletal and cardiac muscle attenuated AICAR-induced hypoglycemia [9]. To further determine 
the contribution of skeletal muscle AMPK to AICAR-induced hypoglycemia, we generated an 
AMPKα1/α2-mKO mouse model in which both AMPK α1 and α2 subunits were specifically 
deleted in skeletal muscle. Deletion of AMPK α1 and α2 subunits caused a substantial decrease 
of TBC1D1-Ser231 phosphorylation but did not alter expression of TBC1D1 and AS160 in 
skeletal muscle (Fig. 1a). Expression and phosphorylation of AMPKα and TBC1D1 remained 
normal in other tissues analyzed (Fig. 1b-c). Intraperitoneal injection of AICAR caused 
hypoglycemia in the AMPKα1/α2f/f control mice (Fig. 1d). Interestingly, this hypoglycemic 
effect of AICAR was blunted in the AMPKα1/α2-mKO mice (Fig. 1d). As expected, glucose 
uptake was completely inhibited in the AMPKα1/α2-deficient soleus and EDL muscle in 
response to AICAR (2 mmol/l) (Fig. 1e-f). Concomitantly, AICAR-stimulated GLUT4 
translocation was impaired in EDL muscle from the AMPKα1/α2-mKO mice (Fig. 1g-h). These 
data confirm previous reports that AMPK controls AICAR-stimulated muscle glucose uptake 
and GLUT4 translocation [6-10, 33], and also demonstrate that muscle AMPK makes a large, if 
not complete, contribution to AICAR-induced hypoglycemia under the conditions used in this 
study. 
The TBC1D1Ser231Ala knockin mutation attenuated the hypoglycemic effect of AICAR 
 Next, we employed the TBC1D1Ser231Ala knockin mice to investigate whether TBC1D1 
mediates the AICAR-induced hypoglycemic effect at downstream of AMPK. Intraperitoneal 
injection of AICAR induced phosphorylation of AMPK and a well-established bone fide AMPK 
substrate ACC in knockin muscle to similar extents as in wild-type muscle (Fig. 2a). In contrast 
and as anticipated, AICAR-stimulated TBC1D1-Ser231 phosphorylation was only detected in 
muscle extracts from the wild-type mice but not knockins (Fig. 2a). The AICAR-stimulated 14-
3-3−TBC1D1 interaction assessed by a 14-3-3 overlay assay was also pronouncedly reduced (by 
over 80%) in TBC1D1 immunoprecipitates from the knockin muscle extracts as compared to the 
wild-type controls (Fig. 2a). As previously reported [27], expression of AS160 remained normal 
in TBC1D1Ser231Ala knockin muscle (Fig. 2a). Interestingly, the hypoglycemic effect of AICAR 
was significantly attenuated in both male and female TBC1D1Ser231Ala knockin mice (6 to 8-
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week-old) (Fig. 2b-c). We previously showed that the TBC1D1Ser231Ala knockin mice were 
tolerant to glucose administration at a young age (less than 4-month-old) [27]. In agreement with 
this report, insulin injection lowered blood glucose levels to similar extents in the young 
TBC1D1Ser231Ala knockin mice and wild-type littermates (10 to 12-week-old) (Fig. 2d). 
AICAR-stimulated glucose uptake was decreased in skeletal muscle from the 
TBC1D1Ser231Ala knockin mice 
 We first examined whether soleus and EDL muscles exhibit different sensitivity to 
AICAR in the glucose uptake assay since they have different fiber composition. To this end, two 
concentrations of AICAR were used to stimulate glucose uptake in wild-type soleus and EDL 
muscles. Glucose uptake rates stimulated by a low concentration of AICAR (0.25 mmol/l) were 
~55% and ~94% of those stimulated by the high concentration of AICAR (2 mmol/l) in soleus 
and EDL muscles, respectively (Fig. 3a), suggesting that EDL muscle is more sensitive to 
AICAR treatment. 
We next investigated whether the TBC1D1Ser231Ala knockin mutation impaired AICAR-
stimulated muscle glucose uptake. Glucose uptake was normal in soleus and EDL muscles from 
the TBC1D1Ser231Ala knockin mice under basal conditions. Upon stimulation with AICAR (2 
mmol/l), glucose uptake rates in the knockin soleus muscle were nearly 20% lower (p = 0.0501) 
than those in the wild-type muscle (Fig. 3b). Upon stimulation with the high concentration of 
AICAR (2 mmol/l), glucose uptake rates were only marginally lower (not statistically 
significant) in the knockin EDL muscle than those in the wild-type muscle (Fig. 3c). 
Interestingly, upon stimulation with a low concentration of AICAR (0.15 mmol/l), glucose 
uptake rates in the knockin EDL muscle were significantly lower by ~17% than those in the 
wild-type muscle (Fig. 3c). These data show that the TBC1D1Ser231Ala knockin mutation 
moderately impaired AICAR-stimulated muscle glucose uptake. 
Fiber composition of both soleus and EDL muscles from the TBC1D1Ser231Ala knockin 
mice had no obvious differences compared with the corresponding muscles from the wild-type 
littermates (Fig. 4a-c), indicating that muscle fiber type switch is not the cause of impaired 
AICAR-stimulated glucose uptake in skeletal muscle from the TBC1D1Ser231Ala knockin mice. 
AICAR-stimulated GLUT4 translocation was impaired in EDL muscle from the 
TBC1D1Ser231Ala knockin mice 
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GLUT4 is the major glucose transporter that mediates AICAR-stimulated glucose uptake 
and it undergoes subcellular translocation onto the plasma membrane upon AICAR stimulation 
[9]. As previously reported [27], GLUT4 expression was normal in EDL muscle from the 
TBC1D1Ser231Ala knockin mice (Fig. 5a-b). However, GLUT4 contents on cell surface determined 
using a photolabeling method was only increased by ~25% in ex vivo EDL muscle from the 
TBC1D1Ser231Ala knockin mice upon stimulation with 0.15 mmol/l AICAR in contrast to an 
increase of ~53% in wild-type control muscle (Fig. 5c), suggesting that defects in GLUT4 
translocation underlie the impaired glucose transport in skeletal muscle from the TBC1D1Ser231Ala 
knockin mice. We also confirmed that AICAR increased phosphorylation of AMPK and ACC in 
ex vivo EDL muscle from both genotypes to similar extents (Fig. 5a). As expected, AICAR 
stimulated TBC1D1-Ser231 phosphorylation in ex vivo EDL muscle from the wild-type mice but 
not from the TBC1D1Ser231Ala knockins (Fig. 5a). 
The TBC1D1Ser231Ala knockin mutation did not impair exercise performance and exercise-
induced muscle glucose uptake in mice 
It has been well established that AMPK regulates exercise performance and exercise-
induced muscle glucose uptake [34]. We then sought to find out whether TBC1D1-Ser231 
phosphorylation might mediate these effects of AMPK. The TBC1D1Ser231Ala knockin mice 
displayed normal exercise performance in both power and endurance running tests (Fig. 6a-d). 
Phosphorylation of AMPK and ACC was increased in the exercised muscle from both genotypes 
to similar extents (Fig. 6e). In contrast, phosphorylation of TBC1D1-Ser231 was only increased in 
the exercised muscle from wild-type mice but not from TBC1D1Ser231Ala knockins (Fig. 6e). 
Exercise robustly increased muscle glucose uptake, which was comparable in skeletal muscle 
from the TBC1D1Ser231Ala knockin mice and wild-type littermates (Fig. 6f-g). The unaltered 
exercise-induced muscle glucose uptake was consistent with the recently reported normal 
contraction-stimulated glucose uptake in skeletal muscle from the TBC1D1Ser231Ala knockin mice 
[27].    
Discussion 
Here we employed the TBC1D1Ser231Ala knockin mouse to study the in vivo function of 
TBC1D1-Ser231 phosphorylation and its subsequent 14-3-3−binding in mediating AMPK-
governed muscle glucose uptake. A major finding of this study is that TBC1D1-Ser231 
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phosphorylation and/or its binding to 14-3-3s regulate AICAR-mediated glucose metabolism at 
both peripheral and whole-body levels downstream of AMPK. 
AICAR is widely used as a tool compound to study AMPK signaling, and it lowers blood 
glucose in an AMPK-dependent manner when administered to mice. Overexpression of a kinase-
dead mutant form of AMPKα2, or genetic ablation of AMPK α2, or β2 can all attenuate the 
hypoglycemic effect of AICAR [6-9]. The contribution of AMPK to AICAR-induced 
hypoglycemia in various organs may depend on fasting status of mice. For instance, our data 
demonstrate that muscle AMPK makes a large, if not complete, contribution to AICAR-induced 
hypoglycemia in mice subjected to partial fasting for 4 h. This hypoglycemic effect is most 
likely due to AICAR-stimulated glucose uptake in skeletal muscle, which is blunted in the 
AMPKα1/α2-mKO mice. However, in overnight-fasted mice, liver AMPK also partially 
mediates AICAR-induced hypoglycemia [35]. Our TBC1D1Ser231Ala knockin mouse is a whole-
body knockin model, which has more lean mass and normal fat mass at a young age (less than 4-
month-old) [27]. Even though skeletal muscle plays a dominant role in AICAR-induced 
hypoglycemia in mice subjected to partial fasting (4 h), it is still possible that the 
TBC1D1Ser231Ala knockin mutation might impair AICAR-induced hypoglycemia through multiple 
organs including skeletal muscle. The TBC1D1Ser231Ala knockin mice have higher plasma IGF1 
levels that activate the PKB pathway in skeletal muscle. Consequently, the PKB activates the 
downstream mTOR pathway, but does not phosphorylate AS160 that is a key regulator for 
muscle glucose uptake [27]. We currently do not know whether IGF1 levels can affect AICAR-
induced hypoglycemia in mice.  
It is worthy of note that the AMPKα1/α2-mKO mice were completely resistant to the 
hypoglycemic effect of AICAR, and glucose uptake was blunted in isolated skeletal muscle from 
our AMPKα1/α2-mKO mice (this study) and other AMPK mouse models even with the high 
concentration of AICAR (2 mmol/l) [6-10]. In contrast, the TBC1D1Ser231Ala knockin mice were 
only partially resistant to the hypoglycemic effect of AICAR, and glucose uptake was impaired 
in their EDL muscle only in response to the low concentration of AICAR (0.15 mmol/l) but not 
the high concentration of AICAR (2 mmol/l). Moreover, the TBC1D1Ser231Ala knockin mutation 
did not impair contraction/exercise-stimulated glucose uptake in skeletal muscle (this study and 
[27]), which is partially mediated by AMPK [9, 34]. One possible explanation is that other 
potential AMPK sites such as Thr499, Ser621, Ser660 and Ser700 on TBC1D1 [19, 36] together with 
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Ser231 might account for the regulation of glucose uptake in response to the high concentration of 
AICAR (2 mmol/l) or muscle contraction. In support of this notion, overexpression of a 
TBC1D1-4P mutant (in which Ser231, Thr499, Thr590, and Ser621 were mutated to Ala) decreased 
contraction-stimulated glucose uptake in mouse skeletal muscle [20]. A second possibility is that 
the related RabGAP AS160 might contribute to AICAR- or contraction-stimulated glucose 
uptake. AICAR as well as muscle contraction could stimulate Ser595 phosphorylation of AS160 
though its role in mediating AICAR- or contraction-stimulated glucose uptake remains to be 
established [22]. Third is the likelihood that factors other than TBC1D1 and AS160 might be 
responsible for muscle glucose uptake in response to the high concentration of AICAR (2 
mmol/l) and to muscle contraction. For example, guanine nucleotide exchange factors (GEFs) 
antagonize effects of RabGAPs on activation of downstream Rabs, and can potentially regulate 
GLUT4 trafficking and glucose uptake. One such GEF, Dennd4C, has recently been identified as 
an important factor in regulating GLUT4 trafficking in adipocytes [37]. It is conceivable that 
such GEFs also exist in muscle and regulate GLUT4 translocation in response to AICAR or 
muscle contraction. Since the TBC1D1 Ser231 phosphorylation and/or its binding to 14-3-3s only 
play a moderate role in mediating AMPK-governed muscle glucose uptake, these knockin mice 
should be useful in helping to identify other putative mediators of AMPK-regulated muscle 
glucose uptake in the future. 
A growing body of evidence shows that genetic manipulation or mutation of the related 
RabGAPs, TBC1D1 and AS160, regulate GLUT4 by modulating both its expression and 
translocation in a complex manner. Insulin-stimulated GLUT4 translocation onto plasma 
membrane was impaired in the AS160Thr649Ala knockin mice although expression of the 
transporter was elevated [25]. In contrast, expression of GLUT4 was decreased in various 
muscles and adipose tissue of the AS160 deficient mouse models [38-40] as well as in skeletal 
muscles from human patients who harbor a pre-mature stop codon Arg684Ter on AS160 [15]. 
Similarly, here we show that the TBC1D1Ser231Ala knockin mutation did not affect GLUT4 
expression but attenuated GLUT4 translocation onto plasma membrane in response to AICAR, 
whereas a natural TBC1D1 deficient mutant mouse and various TBC1D1 knockout mice had 
reduced levels of GLUT4 in their skeletal muscles [14, 41-44]. Interestingly, the reduced 
GLUT4 levels in one of the TBC1D1 knockout mouse models caused a decrease in exercise-
stimulated glucose uptake in nonoxidative muscle fibers and consequently impaired exercise 
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endurance [44]. It has been recently shown that the loss of AS160 GAP activity accelerates 
lysosomal degradation of GLUT4 [40]. A key question remaining to be answered in all the 
TBC1D1 mouse models is whether the effects on GLUT4 translocation or expression are 
dependent on the GAP activity of TBC1D1.  
In summary, the TBC1D1Ser231Ala knockin mutation impacts on insulin-
independent/AICAR-mediated whole-body glucose homeostasis in mouse at least in part through 
impairing muscle GLUT4 translocation and glucose uptake. 
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Figure legends 
Figure 1    AICAR-stimulated glucose clearance and muscle glucose uptake in 
AMPKα1/α2-mKO mice 
a-c. Expression and phosphorylation of AMPKα, TBC1D1 and AS160 in skeletal muscle (a), 
heart (b) and liver (c). 
d. AICAR tolerance test of male AMPKα1/α2f/f and AMPKα1/α2-mKO mice (6-8-week-old). n 
= 5-6.  
e. Glucose uptake in soleus muscle ex vivo in response to AICAR (2 mmol/l). † indicates p < 
0.05 (AMPKα1/α2f/f AICAR vs AMPKα1/α2f/f basal). n = 7. 
f. Glucose uptake in EDL muscle ex vivo in response to AICAR (2 mmol/l). † indicates p < 0.05 
(AMPKα1/α2f/f AICAR vs AMPKα1/α2f/f basal). n = 5-6. 
g-h. GLUT4 staining in EDL muscle fibers in response to AICAR (2 mmol/l). g, representative 
images. h, quantitative data of plasma membrane (PM) GLUT4. At least 100 bracketed regions 
(examples shown in g) from ~20 muscle fibers were quantified per condition/genotype. Bars 
indicate 2 μm in length. † indicates p < 0.05 (AMPKα1/α2f/f AICAR vs AMPKα1/α2f/f basal). 
Statistical analyses were performed via t-test for d, or via two-way ANOVA for e, f and h. 
Figure 2   Glucose clearance in the TBC1D1Ser231Ala knockin mice after intraperitoneal 
injection with AICAR or insulin 
a. Ser231 phosphorylation and 14-3-3 binding of TBC1D1 in skeletal muscle upon AICAR 
stimulation. TBC1D1 proteins were immunoprecipitated from lysates of TA muscle from mice 
intraperitoneally injected with either saline (basal) or AICAR (0.25 mg/g), and subject to 
immunoblotting analysis. Total and phosphorylated ACC, AMPK and AS160 were measured in 
muscle lysates with GAPDH as internal control. 
b. AICAR tolerance test of male mice at 6-8 weeks of age. n = 9-12. 
c. AICAR tolerance test of female mice at 6-8 weeks of age. n = 6. 
d. Insulin tolerance test of male mice at 10-12 weeks of age. n = 6-7. 
Statistical analyses were carried out via t-test. 
Figure 3   Glucose uptake in skeletal muscle ex vivo upon AICAR stimulation 
a. Glucose uptake in EDL and soleus muscle ex vivo in response to AICAR (0.25 mmol/l and 2 
mmol/l). n = 4. 
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b. Glucose uptake in soleus muscle ex vivo in response to AICAR (2 mmol/l). n = 6-7. * 
indicates p < 0.05 (WT AICAR vs WT basal), and † indicates p < 0.05 (TBC1D1Ser231Ala AICAR 
vs TBC1D1Ser231Ala basal).  
c. Glucose uptake in EDL muscle ex vivo in response to AICAR (0.15 mmol/l and 2 mmol/l). n = 
15-21. † indicates p < 0.05 (WT AICAR vs WT basal), and ‡ indicates p < 0.05 (TBC1D1Ser231Ala 
AICAR vs TBC1D1Ser231Ala basal).  
Statistical analyses were performed via t-test for a, or via two-way ANOVA for b and c. 
Figure 4   Muscle fiber composition in soleus and EDL muscles from the wild-type and 
TBC1D1Ser231Ala knockin mice 
a. Representative images of myosin ATPase staining in soleus and EDL muscle for 
determination of muscle fiber composition. Bars indicate 50 μm in length. 
b-c. Percentage of different muscle fibers in soleus (b) and EDL (c) muscle. soleus, n = 4-5; 
EDL, n = 5-7. Statistical analyses were performed via t-test.  
Figure 5   Cell surface GLUT4 contents in EDL muscle ex vivo upon AICAR stimulation 
a. Expression and phosphorylation of TBC1D1, ACC and AMPK, and expression of GLUT4 in 
EDL muscle ex vivo upon AICAR stimulation. Phosphorylation of TBC1D1-Ser231 was 
measured on immunoprecipitated TBC1D1 proteins. 
b. Quantitation of GLUT4 proteins in EDL muscle. The GLUT4 blot from Fig. 5a was used for 
quantitation. n = 6. 
c. Cell surface GLUT4 levels in EDL muscle ex vivo in response to AICAR (0.15 mmol/l). n = 4. 
Representative blots are shown. 
Statistical analyses were performed via t-test for b, or via two-way ANOVA for c. 
Figure 6   Exercise performance and exercise-stimulated muscle glucose uptake in vivo 
a-d. Treadmill running exercise in the wild-type and TBC1D1Ser231Ala mice (3-month-old). a 
(male) and b (female), power test. c (male) and d (female), endurance test. n = 6-15. 
e. Total and phosphorylated TBC1D1, ACC and AMPK in gastrocnemius muscle from rested or 
treadmill-exercised mice (female, 7-8-week-old). 
f-g. In vivo muscle glucose uptake in gastrocnemius (f) and quadriceps (g) from rested or 
treadmill-exercised wild-type and TBC1D1Ser231Ala mice (female, 7-8-week-old). Resting group, 
n = 3-5; Running group, n = 6-7. * indicates p < 0.05 (WT running vs WT resting), and † 
indicates p < 0.05 (TBC1D1Ser231Ala running vs TBC1D1Ser231Ala resting). 
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Statistical analyses were performed via t-test for a-d, or via two-way ANOVA for f-g. 
